Souhaitez-vous accéder aux communiqués récents ?

Phase III trial showed everolimus significantly delayed tumor growth in patients with advanced neuroendocrine tumors (NET) of pancreatic origin [1] Everolimus represents a potentially new targeted...

Novartis a réalisé, au deuxième trimestre, une croissance de 19% de son chiffre d'affaires, à taux de change constants, et un excellent levier opérationnel Chiffre d'affaires net en hausse de 27 %...

Novartis erzielte im zweiten Quartal bei konstanten Wechselkursen ein Umsatzwachstum von 19% sowie eine hervorragende operative Leistungsfähigkeit Der Nettoumsatz stieg um 27% (+19% bei konstanten...

Novartis achieved 19% sales growth in constant currencies and excellent operating leverage in the second quarter Net sales grew 27% (+19% in constant currencies, or cc) to USD 14.9 billion;...

Novartis plans to ship over 30 million doses of Fluvirin vaccine to US customers for 2011-2012 season with sufficient supply to meet customer demand  Early delivery allows for early vaccination...

Largest Phase III study in tuberous sclerosis complex (TSC) showed 35% of patients treated with everolimus had a 50% or greater reduction in SEGA volume versus 0% on placebo[1] Subependymal...

Trial stopped early after positive interim results showed everolimus plus exemestane extended time without tumor growth Postmenopausal ER+HER2- metastatic breast cancer patients whose disease...

Arcapta is the only once-daily long-acting beta2-agonist (LABA) approved in US for maintenance treatment of airflow obstruction in patients with COPD Clinical studies with Arcapta showed...

Onbrez is the only once-daily long-acting beta2-agonist (LABA) approved in Japan for treatment of chronic obstructive pulmonary disease Clinical data show that Onbrez provides rapid and...

GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p<0.001) with comparable efficacy to open-label tiotropium at 12 weeks[1]  NVA237 shown to be well-tolerated in...